Inhibiting CD39 with our product candidate SRF617 provides a dual biological mechanism to fight #cancer by reducing immunosuppressive adenosine and driving the extracellular accumulation of immunostimulatory ATP within the tumor microenvironment. #biotech
https://t.co/7wdgwESIC9